Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773741 | 0.90 | CYP4F2 (0.47) | CYP4F2CYP4A11SMN1; SMN2HTTHPGD | |
| SCHEMBL772929 | 0.83 | CYP4F2 (0.42) | CYP4F2CYP4A11SMN1; SMN2HTTHPGD | |
| SCHEMBL15692289 | 0.77 | CYP4F2 (0.41) | CYP4F2CYP4A11SMN1; SMN2HTTHPGD | |
| SCHEMBL798386 | 0.76 | CYP4F2 (0.50) | CYP4F2CYP4A11LMNA | |
| SCHEMBL5450521 | 0.74 | SPHK1 (0.50) | CYP4F2CYP4A11 | |
| SCHEMBL5449643 | 0.74 | SPHK1 (0.50) | CYP4F2CYP4A11 | |
| SCHEMBL3682206 | 0.71 | SPHK1 (0.54) | SMN1; SMN2HPGDLMNA | |
| SCHEMBL22761937 | 0.69 | CYP4F2 (0.38) | CYP4F2CYP4A11SMN1; SMN2HPGDLMNA | |
| SCHEMBL28594860 | 0.66 | FAAH (0.46) | CYP4F2CYP4A11 | |
| SCHEMBL8333228 | 0.65 | SPHK1 (0.54) | SMN1; SMN2HPGDLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040177-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA | KAREUS THERAPEUTICS, SA (CH) | 2012-03-29 | — | — | WO | disclosed |